Dinesh Kumar 0:04
My name is Dinesh Kumar, I'm Chief Operations Officer at Promaxo. And here to talk about how we are making a difference with our office based MRI system and robotic platform. So it's a busy slide, I just want you to focus on the right side on the numbers. So we're founded in 2016. We are based in Oakland, California, and we got our 510 K in 2021. And since then, we have seen 20% year over year growth in our customer acquisition, and we are well on our path to profitability over the next 12 to 18 months, with a clear pathway to up to 70% gross margins, and more than 30% and EBITDA margins are pretty sizable and defensible IP portfolio with a growing list of publications, clinical and technical and upwards of 75% cancellation date, which again, compared to Senator care is way above anything else can achieve. We operate in a pretty sizable addressable market of $3 billion per year for prostate cancer and diagnosis. And we have sold more than under System and covered more than 30 territories and states. So when we think of MRI rights, MRI is really a gold standard for soft tissue imaging. But Traditional MRIs also, when we think of they're bulky, they are in basement, you have to basically put a large infrastructure around, there is reinforcement and there is shielding, and costly to acquire and maintain. As a result, there is low availability and long waiting period for patients. But also, you can't just use traditional tools under MRI. And until that access to anatomy is pretty cool. And that's where we fit in that Promaxo going to do basically call for prostate from streaming to biopsy to treatment and post treatment follow up. So for screening, we are collecting a lot of data to build machine learning based tissue characterization. But for biopsy and targeted therapy, we are clear now we have an MRI system for doing manual transcranial biopsy and intervention. And the robot or transplant robot for Whitson, RCM robot, we are getting ready to submit for five FTA fighting game. The leadership team again, you know the lot of us here but most of us have decades of experience in urology, robotics and Mr. AI system led by a serial entrepreneur Amadora. So in terms of total market size, so prostate, we see more than a million biopsies per year and a few $100,000 treatments. And when you combine it all, it's almost $3 billion worldwide market per year. And when we look at adjacent markets where we are already laying groundwork, for example, female pelvic floor is 4 billion prostate screening 7 billion and breast is 20 billion total addressable market. This is what the system looks like. From the right side you see our MRI system magnet which about four feet along with the panel. On the left side you see the system with both open and a robot that's meant to go through the bore to transplant intervention. The MRI system is again small footprint you can actually fit it in a very small office in a urology clinic even or ASC and it's very patient and physician friendly. So better outcomes, better detection rates, and reimbursements for physicians and facilities. But for patients it's also less invasive. There is no transsexual approach for prostate. And we only have machine learning based image enhancement and image artifact reduction built in and really collecting data to get to tissue factorization. The robot is still Priya FDA pre 510 K. How do we compare against just standard care so standard of care is really well core to 15 core trust Ecto biopsy where you sample prostate uniformly and we actually have been comparing at most sites we do per lesion we take about two samples per lesion and up to four or five total sample and with that we are getting upwards of 75% detection rates across multiple centers and we upgrade cancer catalyst a third time and we identify more clinically significant cancers. So this is a testimonial from one of our doctors and this patient
Speaker 2 4:36
offering MRI targeted biopsy is a game changer. This is different than an MRI fusion biopsy is offered better patient care, better outcomes and less side effects.
Speaker 3 4:48
I was very worried going into my Promaxo MRI biopsy because I had a traditional biopsy before the recovery from that took a very long time. It was very unpleasant and the procedure itself was extreme. Usually stressful, we
Speaker 2 5:00
can accurately look and find the cancers about any transrectal ultrasound or probe
Speaker 3 5:05
my Promax MRI biopsy gave the doctor exactly what we needed to know, to determine my coarser treatment. There's just not enough words that describe how much easier and how much less impactful the pro Mexico procedure is pro
Speaker 2 5:21
maxtow has enabled me to run clinic and perform biopsies at the same time before I was running to the ASC to do my biopsies. Now I can bring it all in house. And for patients that makes the experience so much more easier. This is a technology that is eons ahead of what we have here in our community. And bringing this on board is really set us apart from the other practices around us. I imagined in the future, we're going to be using this machine for so many different things in our offices, we're just at the tip of the iceberg.
Speaker 3 5:51
My Promax MRI procedure was so easy, and so much less invasive. My recovery time was just days, I had no complications whatsoever. I came out very, very happy.
Speaker 1 6:05
Dr. Mann is not alone, right. So across the board, many other neurologists and key opinion leaders, they have had similar experiences. They come from academic sites, and also from research and private clinics. This is a very busy slide. And that's why it's kind of more exciting for us as well, because these are product roadmap, you want to see it busy. So we have already realized the prostate MRI so we can do prostate biopsy and target treatment. But in clinical and research, we are getting to prostate screening, through data collection and ticket characterization, female pelvic floor, OBGYN indications, and kidney and breast following that. So a robot is p 510. K, so we expect clients by the end of this year or early next year. So a collection of our some of basically our users, so they cover an entire market segment for us. So we go from urologists office to IDs and ACS, but also research centers and university. And some of these customers have actually bought multiple systems as well. We are growing pretty rapidly green is where our current presence is. That includes clinical systems. Blue is where we want to be this year, and we already have been laying groundwork and some old, idealized and orange is where we want to go in 2025. So production capacity is it's reaching up to 120 per year. So that's really where we want to be by the end of this year. So that we can fulfill our demand, but also laying groundwork internationally to optimize our supply chain, but also to basically meet demand in international markets. And this is actually a picture of our contract manufacturer where we build the systems. So I will stop these highlights. I will let you read these. I talked about all of these. But what we are what I'm here for is we are really finishing up our closing our v3 round in anticipation of a big round and if there is an interest in participating in v3 then you know please come and find me. We can do one on one and we can go over more details. Thank you
© 2024 Life Science Intelligence, Inc., All Rights Reserved.
